Cargando…
SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727475/ https://www.ncbi.nlm.nih.gov/pubmed/34987150 http://dx.doi.org/10.1038/s41392-021-00863-2 |
| _version_ | 1784626538060185600 |
|---|---|
| author | Wu, Leyun Zhou, Liping Mo, Mengxia Liu, Tingting Wu, Chengkun Gong, Chunye Lu, Kai Gong, Likun Zhu, Weiliang Xu, Zhijian |
| author_facet | Wu, Leyun Zhou, Liping Mo, Mengxia Liu, Tingting Wu, Chengkun Gong, Chunye Lu, Kai Gong, Likun Zhu, Weiliang Xu, Zhijian |
| author_sort | Wu, Leyun |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8727475 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-87274752022-01-05 SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 Wu, Leyun Zhou, Liping Mo, Mengxia Liu, Tingting Wu, Chengkun Gong, Chunye Lu, Kai Gong, Likun Zhu, Weiliang Xu, Zhijian Signal Transduct Target Ther Letter Nature Publishing Group UK 2022-01-05 /pmc/articles/PMC8727475/ /pubmed/34987150 http://dx.doi.org/10.1038/s41392-021-00863-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter Wu, Leyun Zhou, Liping Mo, Mengxia Liu, Tingting Wu, Chengkun Gong, Chunye Lu, Kai Gong, Likun Zhu, Weiliang Xu, Zhijian SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 |
| title | SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 |
| title_full | SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 |
| title_fullStr | SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 |
| title_full_unstemmed | SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 |
| title_short | SARS-CoV-2 Omicron RBD shows weaker binding affinity than the currently dominant Delta variant to human ACE2 |
| title_sort | sars-cov-2 omicron rbd shows weaker binding affinity than the currently dominant delta variant to human ace2 |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727475/ https://www.ncbi.nlm.nih.gov/pubmed/34987150 http://dx.doi.org/10.1038/s41392-021-00863-2 |
| work_keys_str_mv | AT wuleyun sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT zhouliping sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT momengxia sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT liutingting sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT wuchengkun sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT gongchunye sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT lukai sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT gonglikun sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT zhuweiliang sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 AT xuzhijian sarscov2omicronrbdshowsweakerbindingaffinitythanthecurrentlydominantdeltavarianttohumanace2 |